Soligenix Inc., of Princeton, N.J., published data from an investigator-initiated Phase II trial of orBec (oral beclomethasone dipropionate) showing the drug was well tolerated but did not achieve statistical significance in reducing graft-vs.-host disease (GVHD) following hematopoietic cell transplantation, as previously reported. The data were published in Biology of Blood and Marrow Transplantation. Soligenix halted a Phase III GVHD trial in September after an interim analysis showed it was unlikely to meet its endpoint.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST